Before making decisions about Keytruda (Pembrolizumab), it helps to separate its intended use from its possible side effects and precautions. This guide brings those points together for readers exploring immune and inflammatory conditions, with explanations of treatment purpose, practical use, and questions worth raising with a healthcare professional. Medicine labels and approvals may change, and instructions are not interchangeable across products, strengths, or countries.
Unlike chemotherapy, which attacks rapidly dividing cells directly, Keytruda works on the immune system’s control switches. That difference shapes both its benefits and its side effects, which can appear anywhere in the body and sometimes weeks after an infusion.
This article explains how pembrolizumab works, which cancers it is used for, how infusions are scheduled, and which warning signs deserve a call to your oncology team. Throughout, treatment decisions are framed as what they are: choices made by a cancer care team who knows your diagnosis, test results, and overall health.
What Is Keytruda?
Keytruda is the brand name for pembrolizumab, a laboratory-made antibody designed to attach to a protein on immune cells called PD-1. It belongs to a class of drugs known as immune checkpoint inhibitors. These medicines do not kill cancer cells directly; they release constraints that tumors place on the immune system.
Pembrolizumab is available only by prescription and is administered in a clinic or hospital infusion unit by trained staff. It cannot be taken as a pill and is not something patients handle at home. Since its first approval for advanced melanoma, the number of approved uses has grown steadily, and the current label now covers dozens of indications across solid tumors and blood cancers. That growth is good news, but it also means the details of any one person’s treatment depend heavily on their specific cancer type and biomarker results.
Which Cancers Does Keytruda Treat?
The FDA has approved pembrolizumab for many uses, and the list continues to expand as research matures. Approved settings include, as examples:
- Lung cancer: non-small cell lung cancer in several stages and situations, alone or combined with chemotherapy.
- Melanoma: advanced disease, and as additional treatment in earlier stages after surgery in certain circumstances.
- Head and neck cancer: recurrent or metastatic squamous cell carcinoma in defined settings.
- Hodgkin lymphoma: after certain prior therapies, in relapsed or progressive disease.
- Bladder and urinary tract cancer: urothelial carcinoma in metastatic, earlier-stage, and high-risk settings.
- Other solid tumors: gastric, cervical, esophageal, kidney, liver, and additional cancers, along with selected uses tied to tumor biomarkers regardless of where the cancer started.
Do not treat this list as complete or as a self-assessment tool. Eligibility depends on cancer type, stage, prior treatments, and biomarker testing, and labeling details change over time. Your oncology team confirms whether pembrolizumab is appropriate for your situation by checking the current approved indications and the latest clinical guidance.
How Keytruda Works: Releasing the Immune Brakes
T cells, the immune system’s attack cells, carry built-in safety switches called checkpoints. One of them, PD-1, acts like a brake pedal: when it locks onto its partner proteins on other cells, the T cell stands down. Healthy cells use this system to avoid being attacked by mistake, and cancers exploit it by displaying those partner proteins, effectively wearing a do-not-touch badge.
Pembrolizumab blocks PD-1, which disables the brake. With the checkpoint disengaged, T cells can recognize tumor cells as abnormal and mount an attack. This is why the drug is called a checkpoint inhibitor and why its effects differ from chemotherapy: the immune system does the attacking, and once activated, it can keep working across many tumor sites.
The same mechanism explains the drug’s characteristic risks. When the immune brake is released, immune cells can sometimes attack healthy organs, which is the basis for the immune-mediated side effects described later in this article.
Biomarkers That Guide Keytruda Use
Many pembrolizumab decisions depend on laboratory testing of tumor tissue or blood. These biomarker tests help predict whether checkpoint blockade is likely to help and in which combinations.
| Biomarker | What it measures | Why it matters for treatment |
|---|---|---|
| PD-L1 | A protein level on tumor or immune cells, measured by a scoring test | Higher expression can support pembrolizumab use, often with defined score thresholds, in several cancer types |
| MSI-H / dMMR | Microsatellite instability or deficient mismatch repair, signs the tumor’s DNA repair is faulty | Tumors with this feature often respond to checkpoint blockade, and approved uses extend across tumor types with this finding |
| TMB-H | High tumor mutational burden, meaning many mutations per tumor cell | A high mutation load can make tumors more visible to the immune system and has supported tumor-agnostic approvals |
Biomarker requirements and thresholds differ by indication, and not every use depends on a biomarker. Ask your team which tests were run, what the results showed, and how those results shaped the recommended plan.
How Keytruda Is Given
Treatment takes place in an infusion center. A nurse places an intravenous line, and the dose, calculated either by body weight or as a standard flat dose depending on the protocol, is infused slowly over roughly half an hour. Schedules are commonly every three weeks or every six weeks, set by the oncology team according to the approved regimen for your cancer. The team may give pre-medications if infusion reactions are a concern.
Each visit includes a brief check of symptoms, vital signs, and sometimes blood work before the infusion proceeds. Plan for extra time on visit days, and arrange rides if you feel uncertain about driving afterward. Patients never self-administer this drug, and there is no take-home form; if an appointment must move, call the infusion center promptly so the schedule is adjusted rather than skipped.
Common Side Effects of Keytruda
Most people experience some side effects, and most are manageable with early communication. Because pembrolizumab recruits the immune system, its effects differ from chemotherapy and can involve glands and organs that chemotherapy rarely touches.
| More common | Less common but notable |
|---|---|
| Fatigue that builds gradually across treatment cycles | Cough or shortness of breath |
| Rash or itching, usually on the trunk and limbs | Joint pain and stiffness |
| Loose stools or mild diarrhea | Thyroid changes on blood tests, either underactive or overactive |
| Reduced appetite or nausea | Eye dryness or irritation |
Report anything new at each visit, even if it seems minor. Patterns matter: a skin rash plus diarrhea, for example, reads differently to an oncologist than either symptom alone, and early adjustments prevent escalation.
Serious Side Effects and the Boxed Warning
Keytruda carries a boxed warning for immune-mediated adverse reactions, which are the most important safety issue with this class. When the checkpoint brake is released, the immune system can inflame healthy organs, sometimes severely and sometimes late in treatment or after it ends. Organs affected can include:
- Lungs: pneumonitis, felt as new or worsening cough, chest pain, or breathlessness
- Colon: colitis, with diarrhea, blood in stool, or severe abdominal cramping
- Liver: hepatitis, showing up as yellowing skin or eyes, dark urine, or abnormal liver labs
- Endocrine glands: thyroid, adrenal, or pituitary inflammation, and new type 1 diabetes, with symptoms such as profound fatigue, weight change, dizziness, or intense thirst
- Kidneys, skin, brain, nerves, heart, and muscles: nephritis, severe rashes, encephalitis or confusion, muscle weakness, chest pain, and other immune attacks
The key principle is that severe immune reactions are treated early, usually with corticosteroids and sometimes other immunosuppressive medicines, while pembrolizumab is paused or stopped. Delaying treatment makes these reactions harder to control, so teams ask patients to call about symptoms rather than wait for the next appointment. Call your team the same day for any new breathlessness, persistent diarrhea, severe rash, unexplained weight loss, extreme fatigue, or confusion, and seek emergency care for chest pain, trouble breathing, or sudden weakness.
Two further warnings round out the label. Infusion reactions, occasionally severe, can occur during or shortly after administration, which is why infusions happen with monitoring. And patients who have had, or later receive, an allogeneic stem cell transplant face elevated risks of serious complications, including graft-versus-host disease, so transplant history must be shared with the oncology team.
Who Should Use Keytruda with Caution?
Checkpoint inhibition changes immune behavior, so certain backgrounds require extra planning before the first dose.
Other Medicines and Immune Conditions
People with autoimmune diseases such as lupus, Crohn’s disease, or rheumatoid arthritis can sometimes receive checkpoint inhibitors, but the risk of flares is higher and requires coordination with their other specialists. High-dose corticosteroids or immunosuppressants taken before starting may blunt the treatment, so teams review timing carefully. Bring a complete list of medicines, including inhalers, injections, and supplements, and mention every past immune reaction, because those histories shape how vigilantly side effects are chased.
Pregnancy and Breastfeeding
Pembrolizumab can harm a developing fetus, and it is not used during pregnancy. People who could become pregnant are advised to use effective contraception during treatment and for some months after the final dose, with the exact interval confirmed by the oncology team. Breastfeeding is not recommended during treatment. Anyone who is pregnant or becomes pregnant during therapy should contact their care team immediately, and pregnancy exposures are typically discussed with maternal-fetal medicine specialists.
Use in Children and Older Adults
Some approved uses extend to children and adolescents with specific cancers, and pediatric immunotherapy is managed exclusively by pediatric oncology teams. Older adults receive pembrolizumab frequently, and age alone does not disqualify anyone; however, coexisting conditions, baseline organ function, and other medicines influence how aggressively side effects are managed. The team weighs these factors individually rather than by age cutoffs.
Storage and Handling
Patients do not store or handle Keytruda. The pharmacy and infusion center take responsibility for refrigerated storage, sterile preparation, and disposal of supplies. Your role is scheduling: keep infusion appointments, arrive on time, and call ahead if you have fever or new symptoms, since treatment may be postponed until the team evaluates you. If you travel, coordinate infusion dates with centers near your destination only with your oncologist’s involvement, because continuity of protocols and records matters for a drug with this side-effect profile.
How Soon Keytruda Works and How Long Treatment Lasts
Responses vary widely. Some people see tumors shrink on early scans, while others need several cycles before imaging shows clear change, and a smaller group benefits for long periods even after difficult starts. Teams typically order imaging on a set schedule during the first months, then adjust the rhythm based on results. Because immune responses can evolve in ways that look confusing on a single scan, oncologists interpret early changes in context rather than reacting to one image.
Duration depends on the indication, the response, and how side effects evolve. Some regimens run for a fixed period around or after surgery, while treatment for advanced disease often continues as long as it keeps working and remains tolerable. Ask your team how they will define success, what scan schedule they plan, and under what circumstances they would pause or stop therapy, so expectations are anchored to your specific protocol.
Alternatives and Comparisons
Pembrolizumab is one of several checkpoint inhibitors. Others, including nivolumab, atezolizumab, durvalumab, and cemiplimab, work on related switches, and approved indications overlap but rarely coincide exactly. Selection depends on tumor type, biomarkers, stage, prior therapy, and logistics, and oncologists compare these options against the strength of evidence in each specific cancer.
Immunotherapy also sits among broader choices: chemotherapy, radiation, hormone therapy, targeted drugs matched to tumor mutations, surgery, and clinical trials. Many modern regimens combine approaches, such as pembrolizumab with chemotherapy or with other agents, when evidence shows the combination outperforms either alone. None of these options is universally superior, and a well-matched trial can be a strong choice rather than a last resort. Ask your team to explain why the selected path fits your cancer better than the alternatives.
Questions to Ask Your Cancer Care Team
- Which approved indication applies to me, and which biomarker tests guided that decision?
- Will pembrolizumab be given alone or with other treatments, and why?
- What infusion schedule should I expect, and how long is each visit?
- Which symptoms should prompt a same-day call versus an emergency visit?
- How will we know the treatment is working, and when is my first scan?
- What happens if I develop an immune-related side effect, and how would it be treated?
- Are there clinical trials that fit my diagnosis as well as or better than standard care?
Writing answers down, or bringing someone to appointments to take notes, makes it easier to track changes across cycles and to act quickly when something feels different.
Frequently Asked Questions
Is Keytruda chemotherapy?
No. It is an immunotherapy, a monoclonal antibody that adjusts immune checkpoints. It does not poison dividing cells the way chemotherapy does, which is why hair loss and blood count drops are not typical effects, while immune-related inflammation is the characteristic concern.
How long does each infusion take?
The infusion itself generally takes about half an hour, but visits last longer once check-in, vital signs, symptom review, and post-infusion observation are included. Ask the infusion center about typical visit length and busiest times when planning your day.
What are biomarker tests, and do I need them?
They are lab tests on tumor tissue or blood that look for features such as PD-L1 expression, MSI-H or dMMR status, or high mutational burden. Many Keytruda indications require or are guided by them, and your team arranges testing before or early in treatment planning.
Why can side effects appear weeks after an infusion?
The drug changes immune regulation, and immune attacks on organs can build gradually or emerge after several cycles, occasionally after treatment ends. That delayed pattern is why teams emphasize symptom reporting throughout and for a period after the last dose.
What if I miss a scheduled infusion?
Call the infusion center as soon as possible. Because schedules are built around three- or six-week intervals, the team will calculate the safest way to resume, which usually means rebooking promptly rather than compressing doses.
Can Keytruda be combined with other cancer treatments?
Yes, and many approved regimens pair it with chemotherapy, other agents, or additional therapies depending on the cancer. Combining can raise side-effect risks, so protocols specify exactly how drugs are sequenced and monitored.
Will I lose my hair on pembrolizumab?
Hair loss is not a typical effect of Keytruda by itself, unlike many chemotherapies. If your regimen includes chemotherapy as well, hair changes may come from that component, and your team can clarify which drug is responsible for what.
Conclusion
Keytruda changed modern oncology by turning the immune system’s own brakes into a treatment target, and its approved uses now span many cancer types and biomarker-defined situations. Its strengths come with a distinctive bargain: effects can be durable, but immune-mediated side effects demand attention, fast reporting, and early treatment with steroids when they turn serious. The most useful things a patient can do are straightforward: know your biomarker results, keep infusion schedules, report new symptoms the day they appear, and keep an open line to the oncology team. Those habits, combined with honest conversations about goals and alternatives, make checkpoint therapy as safe and effective as current medicine allows.
Medical Disclaimer
Cancer therapy decisions are complex and personal, so the information here is background for conversations with your oncology team, not a substitute for them.
Medical Disclaimer: This article is for informational and educational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Follow the official product instructions and seek urgent medical assistance for a medical emergency.
References and Sources
- DailyMed: Keytruda (pembrolizumab) prescribing information — official label with current indications, dosing, and boxed warning details.
- National Cancer Institute — authoritative information on immunotherapy, cancer types, and clinical trials.
- MedlinePlus: Drug Information — National Library of Medicine consumer reference.
- Keytruda official site — manufacturer resources on indications, infusion scheduling, and patient support.
- Drugs@FDA — approval history and labeling records for pembrolizumab.